Clinical pharmacokinetic considerations in the elderly. An update

Clinical Pharmacokinetics

Volumn 33, Issue 4, 1997, Pages 302-312

  Kinirons, Mark T ^a,c   Crome, Peter ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KEELE UNIVERSITY   (United Kingdom)

^c GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450;

CHIRALITY; DRUG CLEARANCE; DRUG METABOLISM; ENVIRONMENTAL FACTOR; ENZYME INDUCTION; ENZYME INHIBITION; ETHNOLOGY; FOOD INTAKE; GERIATRICS; PHARMACOKINETICS; PRIORITY JOURNAL; REVIEW;

EID: 0030982413     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199733040-00005     Document Type: Review

References (106)

1. Dawling S, Crome P. Clinical pharmacokinetics in the elderly: an update. Clin Pharmacokinel 1989; 17: 236-63
2. Brian WR, Sari M-A, Iwasaki M, et al. Catalytic activities of human liver cytochrome P-450 IIIA4 expressed in saccharomyces cerevisiae. Biochemistry 1990; 29: 11280-92
3. Guengerich FP, Brian WR, Iwasaki M, et al. Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P450IIIA4. J Med Chem 1991; 34: 1838-44
4. Wrighton SA. The human hepatic cytochromes P450 involved in human metabolism. Crit Toxicol 1992; 22: 1-21
5. Mahgoub A, Idle R, Dring LG, et al. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977; 2: 584-6
6. Watkins PW, Wrighton SA, Maurel P, et al. Identification of an inducible form of cytochrome P-450 in human liver. Proc Natl Acad Sci 1985; 82: 6310-4
7. Guengerich FP, Turvy CG. Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. J Pharm Exp Ther 1991; 256: 1189-94
8. Vestal RE, Norris AH, Tobin JD, et al. Antipyrine metabolism in man: influence of age, alcohol, caffeine and smoking. Clin Pharmacol Ther 1975; 18: 425-32
9. Wood AJJ, Vestal RE, Branch RA, et al. Effects of age and cigarette smoking on propranolol disposition. Clin Pharmacol Ther 1979; 26: 8-15
10. Durnas C, Loi CM, Cusack BJ. Hepatic drug metabolism and ageing. Clin Pharmacokinet 1990; 19: 359-89
11. Woodhouse K. Drugs and the liver. Part III: ageing of the liver and the metabolism of drugs. Biopharm Drug Dispos 1992; 13: 311-20
12. Schmucker DL, Woodhouse KW, Wang RK, et al. Effect of age and gender on in vivo properties of human liver microsonal mono-oxygenases. Clin Pharmacol Ther 1990; 48: 365-74
13. Woodhouse K, James OFW. Hepatic drug metabolism and ageing. Br Med Bull 1990; 46: 22-35
14. Yelland C, Summerbell J, Nicholson E, et al. The association of age with aspirin esterase activity in human liver. Age Ageing 1991; 20: 16-8
15. Wynne HA, Kamali F, Edwards C, et al. Effect of ageing upon warfarin dose requirements: a longitudinal study. Age Ageing 1996; 25: 429-31
16. Ayesh R, Idle JR, Richie JC, et al. Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature 1984; 312: 169-70
17. Baer AN, McAllister CB, Wilkinson GR, et al. Altered distribution of debrisoquine oxidation phenotypes in patients with systemic lupus erythematosus. Arthritis Rheum 1986; 29: 843-850
18. Kaisary A, Smith P, Jaczq E, et al. Genetic predisposition to bladder cancer, ability to hydroxylate debrisoquine and mephenytoin as risk factors. Cancer Res 1987; 47: 5488-93
19. Persad RA, Fleming CM, Wilkinson GR, et al. Bladder cancer recurrance and its association with cytochrome P450IID6 activity. Prog Clin Biol Res 1992; 378: 19-27
20. Fleming C, Persad R, Kaisery A, et al. Low activity of N-hydroxylation as a susceptibility risk factor in aggressive bladder cancer. Pharmacogenetics 1994; 4: 194-207
21. Johanssen I, Lundqvist E, Bertilsson L, et al. Inherited amplification of an active gene in cytochrome P450 CYP2D6 locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 1993; 90: 11825-9
22. Bourdi M, Gautier JC, Mircheva J, et al. Anti-liver microsomes antibodies and dihydralazine-induced hepatitis: specificity of auto-antibodies and inductive capacity of the drug. Mol Pharmacol 1992; 42: 280-5
23. Armstrong M, Daly AK, Cholerton S, et al. Mutant debrisoquine hydroxylation genes in Parkinson's disease. Lancet 1992; 339: 1017-8
24. Smith AD, Grough AC, Leigh PN, et al. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet 1992; 339: 1375-7
25. Stevenson G, Williams AC, Waring RH, et al. Xenobiotic metabolism in motor neurone disease. Lancet 1988; 1: 644-7
26. Bhamre S, Anandatheerathavarada HK, Shankar SK, et al. Purification of multiple forms of cytochrome P450 from a human brain and reconstitution of analytic activity. Arch Biochem Biophys 1993; 301: 251-5
27. Boucher BA, Kuhl DA, Fabian TC, et al. Effect of neurotrauma on hepatic drug clearance. Clin Pharmacol Ther 1991; 50: 487-97
28. Williams SJ, Farrell GC. Inhibition of antipyrine metabolism by interferon. Br J Clin Pharmacol 1986; 22: 610-2
29. Williams SJ, Baird-Lambert JA, Farrell GC. Inhibition of theophylline metabolism by interferon. Lancet 1987; II: 939-41
30. O'Mahony SM, George G, Westlake H, et al. Plasma aspirin esterase activity in elderly patients undergoing elective hip replacement and with fractured neck of femur. Age Ageing 1945; 23: 338-41
31. Kinirons MT, Lyons D. Pitfalls in prescribing for the elderly. Br J Hosp Med. In press
32. Hunt CM, Westerkam WR, Stave G, et al. Hepatic cytochrome P-4503A (CYP3A) activity in the elderly. Mech Ageing Dev 1992; 64: 189-99
33. Hunt CM, Westerkam WR, Stave GM. Effects of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 1992; 44: 275-83
34. Knodell RG, Dubey RK, Wilkinson GR, et al. Oxidative metabolism of hexobarbital in human liver: relationship to polymorphic S-mephenytoin 4-hydroxylation. J Pharmacol Exp Ther 1988; 245: 845-9
35. Miglioli PA, Pivetta P, Strazzabosco M, et al. Effect of age on single and multiple dose pharmacokinetics of erythromycin. Eur J Clin Pharmacol 1990; 39: 161-4
36. Robertson DRC, Waller DG, Renwick AG, et al. Age related changes in the pharmacokinetics and pharmacodynamics of nifedipine. Br J Clin Pharmacol 1988; 25: 297-305
37. Loi CM, Parker BM, Cusack BJ, et al. Aging and drug interactions: III. Individual and combined effects of cimetidine and cimetidine and ciprofloxacin on theophylline metabolism in healthy male and female nonsmokers. J Pharmacol Exp Ther 1997; 80: 627-37
38. Chandler MH, Scott SR, Blouin RA. Age associated steroselective alterations in hexobarbital metabolism. Clin Pharmacol Ther 1988; 43: 436-41
39. Klotz U, Avant GR, Hoyumpa A, et al. The effects of age and liver disease on the disposition and elimination of diazepam in adult man. J Clin Invest 1975; 55: 347-59
40. May DG, Porter J, Wilkinson GR, et al. Frequency distribution of dapsone N-hydroxylase: a putative probe for P4503A4 activity in a Caucasian population. Clin Pharmacol Ther 1994; 55: 492-500
41. O'Shea D, Davis S, Kim RB, et al. Effect of fasting and obesity in humans on the 6-hydroxylation of chloroxazone: a putative probe for CYP2E1 activity. Clin Pharmacol Ther 1996; 56: 359-67
42. Kim R, O'Shea D, Wilkinson GR. Relationship in healthy subjects between CYP2E1 genetic polymorphism and the 6-hydroxylation of chlorzoxazone: a putative measure of CYP2E1. Pharmacogenetics 1994; 4: 162-5
43. Zhou HH, Anthony LB, Roden DM, et al. Quinidine reduces clearence of (+)-propranolol more than ( )-propranolol through marked reduction of 4-hydroxylation. Clin Pharmacol Ther 1990; 47: 686-93
44. Kinirons MT, O'Shea D, Downing TE, et al. Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men. Clin Pharmacol Ther 1993; 54: 621-9
45. Heim M, Meyer U. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 1990; 336: 529-32
46. Swift CG, Homeida M, Roberts CJC. Antipyrine disposition and liver size in the elderly. Eur J Clin Pharmacol 1978; 14: 149-52
47. Zhou HH, Koshaji RP, Silberstein DJ, et al. Racial differences in drug response: altered sensitivity to and clearance of propranolol in men of Chinese descent as compared to American whiles. N Engl J Med 1989; 320: 565-70
48. Zhou HH, Sheller JR, Nu H, et al. Ethnic differences in response to morphine. Clin Pharmacol Ther 1993; 54: 507-13
49. Caraco Y, Lagerstrom PO, Wood AJJ. Omeprazole disposition in Caucasians and Chinese subjects [abstract]. Clin Pharmacol Ther 1995; 57: 216A
50. Kalow W. Interethnic variation in drug metabolism. Trends Pharmacol Sci 1991; 12: 102-5
51. Wood AJJ, Zhou HH. Ethnic differences in drug disposition and responsiveness. Clin Pharmacokinet 1991; 20: 350-73
52. Schellans JHM, Van Der Wart JHF, Danhof M, et al. Relationship between the metabolism of antipyrine, hexobarbitone and theophylline, in man as assessed by a cocktail approach. Br J Clin Pharmacol 1988; 26: 373-84
53. Stewart DA, Taylor J, Ghosh S, et al. Terodiline causes polymorphic ventricular tachycardia due to reduced heart rule and prolongation of QT interval. Eur J Clin Pharmacol 1992; 42: 577-80
54. Hallen B, Bogentoft S, Sandquist S, et al. Tolerability and steady state pharmacokinetics of terodiline and its main metabolites in elderly patients with urinary incontinance. Eur J Clin Pharmacol 1989; 36: 487-93
55. Watkins PB, Wrighton SA, Schuetz EG, et al. Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J Clin Invest 1987; 80: 1029-36
56. Peters WH, Kremers PG. Cytochromes P450 in the intestinal mucosa of man. Biochem Pharmacol 1989; 38: 1535-42
57. Kolars JC, Swini WM, Merion RM, et al. First-pass metabolism of cyclosporin by the gut. Lancet 1991; 338: 1488-90
58. Kolar JC, Schmiedin-Ren P, Schuetz J, et al. Identification of rifampicin-inducible P450IIIA4 (CYP3A4) in human small bowel enteroeytes. J Clin Invest 1992; 90: 1871-8
59. Kinirons MT, Lang CC, Brown RM, et al. Intestinal cytochrome P45D3A: studies in coeliac disease as a human model [abstract]. Therapie 1995; Suppl.: 71A
60. Schuetz EG, Schuetz JD, McLean Grogan W, et al. Expression of cytochrome P450 3A in amphibian, rat and human kidney. Arch Biochem Biophysics 1992; 294: 206-14
61. Tyndale RF, Sunahara R, Inaba T, et al. Neuronal cytochrome P4502D1 (debrisoquine/sparteine-type). Potent inhibition by () cocaine and nucleoside sequence identity to human hepatic P450 gene CYP2D6. Mol Pharmacol 1991; 40: 63-8
62. Kivisto KT, Fritz P, Linder A, et al. Immunohistochemical localisation of cytochrome P450 3A in human pulmonary carcinomas and normal bronchial tissue. Histochemistry 1995; 103: 25-9
63. Williams D, Woodhouse K. The relationship between age and cutaneous aryl hydrocarbon hydrxylase (AHH) activity. Age Ageing 1995; 24: 213-6
64. Kaminsky LS, Fasco MJ. Small intestine cytochromes P450. Crit Rev Toxicol 1992; 21: 407-22
65. Wheller CW, Wrighton SA. Detection of human lung cytochromes P450 that are immunochemically related to cytochrome P4502E1 and cytochrome P4503A4. Biochem Pharmacol 1992; 44: 183-6
66. Kolars JC, Lown KS, Scmiedlin-Ren P, et al. CYP3A gene expression in human gut epithelium. Pharmacogenetics 1994; 4: 247-59
67. Lucey MR, Kolars JC, Merion RM, et al. Cyclosporin toxicity at therapeutic blood levels and cytochrome P-450 3A. Lancet 1990; 355: 11-5
68. Webber IR, Peters WH, Back DJ. Cyclosporin metabolism by human gastrointestinal mucosal microsomes. Br J Clin Pharmacol 1993; 33: 661-4
69. Guengerich FP. Inhibition of oral contraceptive steroid-metabolizing enzyme by steroids and drugs. Am J Obstet Gynecol 1991; 63: 2159-63
70. Gupta SK, Bakran A, Johnson RW, et al. Cyclosporin-erythromycin interaction in renal transplant patients. Br J Clin Pharmacol 1989; 27: 475-81
71. Yee GC, Stanley DL, Passa LJ, et al. Effect of grapefruit juice on blood cyclosporin concentration. Lancet 1995; 345: 955-6
72. Nolan L, O'Malley K. Prescribing for the elderly: Part 1. Sensitivity of the elderly to adverse drug reactions. J Am Geriatr Soc 1988; 36: 142-9
73. Woodhouse KW, Wynne H, Baillie S, et al. Who are the frail elderly? Q J Med 1988; 68: 505-6
74. William FM, Wynne H, Woodhouse KW, et al. Plasma aspirin esterase: the influence of age and frailty. Age Ageing 1989; 18: 39-42
75. Wynne H, Cope LH, Herd MD, et al. The association of age and frailty with paracetamol conjugation in man. Age Ageing 1990; 19: 419-24
76. Wynne H, Yelland C, Cope LH, et al. The association of age and frailty in the pharmacokinetics and pharmacodynamics of metadopramide. Age Ageing 1993; 22: 354-9
77. Groen H, Horan MA, Roberts NA, et al. The relationship between phenazone (antipyrine) metabolite formation and theophylline metabolism in healthy and frail elderly women. Clin Pharmacokinet 1993; 25: 136-44
78. Isreal BC, Blouin RA, McIntyre W, et al. Effects of interferon-monotherapy on hepatic drug metabolism in cancer patients. Br J Clin Pharmacol 1993; 36: 229-35
79. Zhou HH, Whelan E, Wood AJJ. Lack of effect of age on the stereochemical disposition of propranolol. Br J Clin Pharmacol 1992; 33: 121-3
80. Chirrey LA, Tan SC, Hutt AJ, et al. Pharmacokinetics of ibuprofen enantiomers in young and elderly volunteers. Age Ageing 1995; 25 Suppl. 1: P43
81. Wynne H, Cope L, Kelly P, et al. The influence of age, liver size and enantiomer concentrations on warfarin sensitivity. Br J Clin Pharmacol 1995; 40: 203-7
82. Vestal RE, Wood AJJ, Branch RA, et al. Effects of age and cigarette smoking on propranolol disposition. Clin Ther Pharmacol 1979; 26: 8-15
83. Salem SA, Rajjayabun P, Shepard AM, et al. Reduced induction of drug metablism in the elderly. Age Ageing 1978; 7: 68-73
84. Twum-Burina Y, Finnegan T, Habash AI, et al. Impaired enzyme induction by rifampicin in the elderly. Br J Clin Pharmacol 1984; 17: 595-7
85. George G, Wynne H, Woodhouse KW. The association of age with induction of drug metabolising enzymes in human monocytes. Age Ageing 1990; 19: 364-7
86. George G, Wynne H, Woodhouse KW. Age and the rate of induction of aryl hydrocarbon hydroxylase in isolated peripheral blood monocytes. Age Ageing 1991; 20: 421-3
87. George G, O'Mahony S, Woodhouse K. Age, smoking and activity of mono-oxygenase aryl hydrocarbon hydroxylase in isolated human peripheral blood monocytes. Age Ageing 1994; 23: 421-4
88. Bammel A, van der Mee K, Ohnhaus EE, et al. Divergent effects of different enzyme-inducing agents on endogenous and exogenous testosterone. Eur J Clin Pharmacol 1992; 42: 641-4
89. Guengerich FP. Characterisation of human cytochrome P450 enzymes. FASEB J 1992; 6: 745-8
90. Rost KL, Brosicke H, Heinmeyer G, et al. Specific and dose dependent enzyme induction by omeprazole in human beings. Hepatology 1995; 20: 1204-12
91. Ochs HR, Greenblatt DJ, Burstein ES. Lack of influence of cigarette smoking on triazolam pharmacokinetics. Br J Clin Pharmacol 1987; 23: 759-63
92. Zhou HH, Anthony L, Wood AJJ, et al. Induction of polymorphic 4-hydroxylation of S-mephenytoin by rifampicin. Br J Clin Pharmacol 1990; 30: 471-5
93. Atiba JO, Blaschke T, Wilkinson GR. Effects of ketoconazole on the polymorphic 4-hydroxylation of S-mephenytoin and debrisoquine. Br J Clin Pharmacol 1989; 28: 161-5
94. Kinirons MT, Morike K, Shay S, et al. Does selective inhibition of cytochrome P450s occur with aging? [abstract]. Clin Res 1994; 42: 215A
95. Kinirons MT, Krivoruk Y, Wilkinson GR, et al. Cytochrome P4503A and the dapsone recovery ratio: lack of inhibition by ketoconazole [abstract]. Clin Pharmacol Ther 1995; 57: 186A
96. Bailey DG, Spence JD, Munoz C, et al. Interaction of citrus juices with felodipine and nifedipine. Lancet 1991; 337: 268-9
97. Ameer B, Weintraub RA. Drug interactions with grapefruit juice. Clin Pharmacokinet 1997 Aug; 33 (2): 103-21
98. Ahsan CH, Renwick AG, Macklin B, et al. Ethnic differences in the pharmacokinetics of oral nifedipine. Br J Clin Pharmacol 1991; 31: 399-403
99. Ahsan CH, Renwick AG, Waller DG, et al. The influence of dose and ethnic origins on pharmacokinetics of nifedipine. Clin Pharmacol Ther 1993; 54: 329-38
100. Raschid TJ, Martin U, Clarke H, et al. Factors affecting the absolute bioavailability of nifedipine. Br J Clin Pharmacol 1995; 40: 51-8
101. Houghton IT, Chan K, Wong YC, et al. Pethidine pharmacokinetics after intramuscular dose: a comparison in Caucasian, Chinese and Nepalese patients. Methods Find Exp Clin Pharmacol 1992; 14: 451-8
102. Tomatore KM, Biocevich DM, Reed K, et al. Methylprednisolone pharmacokinetics, cortisol response and adverse effects in black and while renal transplant recipients. Transplantation 1995; 59: 729-36
103. Lam YW, Jann MW, Chang WH, et al. Intra- and inter-ethnic variability in reduced haloperidol to haloperidol ratios. J Clin Pharmacol 1995; 35: 128-36
104. Chiba K, Ishizaki T, Wilkinson GR. Chlorzoxazone (CZX) 6-hydroxylation in Japanese and Caucasians [abstract]. Clin Pharmacol Ther 1995; 57: 217A
105. Zhou HH, Adedoyin A, Wood AJJ. Differing effects of atropine on heart rate in Chinese and White subjects. Clin Pharmacol Ther 1992; 52: 120-4
106. Monahan BP, Ferguson CL, Killeavy ES, et al. Torsades de pointes occurring in association with terfenadine use. JAMA 1990; 264: 2788-90